Last reviewed · How we verify

NCT02743585: RABbIT

Impact of Rapid Pathogen Identification From Blood Cultures (RABbIT)

Status unknown NA Last updated 10 September 2019
What this trial tests

NA trial testing Filmarray Blood Culture ID (BCID) panel in Bacteremia in 832 participants. Status unknown.

Timeline
20 March 2017
Primary endpoint
2 July 2019
2 July 2020

Quick facts

Lead sponsorTan Tock Seng Hospital
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposediagnostic
Enrollment832
Start date20 March 2017
Primary completion2 July 2019
Estimated completion2 July 2020
Sites1 location across Singapore

Drugs / interventions tested

Conditions studied

Sponsor

Tan Tock Seng Hospital

Who can join

Adults 21 to 103, any sex, with Bacteremia or Sepsis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Septic shock carries high mortality, which may be exacerbated by inappropriate initial therapy. Inappropriate therapy may result from unanticipated antimicrobial resistance. Conversely, positive blood cultures may result from contamination, leading to unnecessary therapy and procedures and possibly prolonged hospitalization. Clinicians may also resort to broad spectrum antimicrobials and be hesitant to de-escalate while awaiting susceptibility results. The investigators hypothesize that rapid identification of pathogens and antimicrobial resistance will ameliorate the above problems and improve time to optimal therapy, avoid unnecessary therapy and ultimately improve patient outcomes. While there are a number of in-vitro and uncontrolled clinical studies, there is a paucity of well-designed clinical trials objectively examining the real-world clinical and health-economic impact of such technology. To date only one randomised trial has been performed in the US (ClinicalTrials.gov NCT01898208), at a setting with low endemic rates of antimicrobial resistance. This is a companion study to NCT01898208. The investigators aim to study the clinical impact and cost-effectiveness of a strategy for rapid pathogen and resistance detection in a setting with a moderate to high levels of antimicrobial resistance.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. An Update on Recent Clinical Trial Data in Bloodstream Infection.
    Stewart AG, Simos P, Sivabalan P, Escolà-Vergé L, et al · · 2024 · cited 5× · PMID 39596730 · DOI 10.3390/antibiotics13111035

Verify or expand the search:

Other recruiting trials for Bacteremia

Currently open trials in the same condition.

Other Tan Tock Seng Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02743585.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing